Geron Corporation (GERN) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Geron Corporation (GERN) has a cash flow conversion efficiency ratio of -0.275x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-62.91 Million) by net assets ($229.11 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Geron Corporation net asset quality index to measure how much of total assets are equity-financed.
Geron Corporation - Cash Flow Conversion Efficiency Trend (1996–2025)
This chart illustrates how Geron Corporation's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check Geron Corporation (GERN) cash earnings ratio to evaluate the quality of earnings relative to operating cash generation.
Geron Corporation Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Geron Corporation ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
S.J.S. Enterprises Limited
NSE:SJS
|
0.122x |
|
Xencor Inc
NASDAQ:XNCR
|
-0.049x |
|
Anhui Huaren Health Pharmaceutical Co. Ltd. Cl A
SHE:301408
|
N/A |
|
Abacus Life Inc.
NASDAQ:ABL
|
-0.075x |
|
engcon AB Cl B
ST:ENGCON-B
|
0.079x |
|
Xinke Material
SHG:600255
|
-0.100x |
|
Ripley Corp
SN:RIPLEY
|
-0.016x |
|
Standard Motor Products Inc
NYSE:SMP
|
-0.059x |
Annual Cash Flow Conversion Efficiency for Geron Corporation (1996–2025)
The table below shows the annual cash flow conversion efficiency of Geron Corporation from 1996 to 2025. For the full company profile with market capitalisation and key ratios, see Geron Corporation market cap and net worth.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $225.87 Million | $-111.04 Million | -0.492x | +36.97% |
| 2024-12-31 | $280.32 Million | $-218.62 Million | -0.780x | -15.28% |
| 2023-12-31 | $247.95 Million | $-167.74 Million | -0.677x | +57.51% |
| 2022-12-31 | $80.00 Million | $-127.38 Million | -1.592x | -110.65% |
| 2021-12-31 | $126.42 Million | $-95.56 Million | -0.756x | -139.23% |
| 2020-12-31 | $210.95 Million | $-66.65 Million | -0.316x | +2.57% |
| 2019-12-31 | $135.16 Million | $-43.83 Million | -0.324x | -174.34% |
| 2018-12-31 | $177.73 Million | $-21.01 Million | -0.118x | +40.31% |
| 2017-12-31 | $103.80 Million | $-20.56 Million | -0.198x | -31.94% |
| 2016-12-31 | $122.38 Million | $-18.37 Million | -0.150x | +11.83% |
| 2015-12-31 | $142.13 Million | $-24.20 Million | -0.170x | -338.00% |
| 2014-12-31 | $130.71 Million | $9.35 Million | 0.072x | +111.65% |
| 2013-12-31 | $59.76 Million | $-36.68 Million | -0.614x | +4.66% |
| 2012-12-31 | $85.65 Million | $-55.15 Million | -0.644x | -51.28% |
| 2011-12-31 | $146.60 Million | $-62.39 Million | -0.426x | -85.19% |
| 2010-12-31 | $192.74 Million | $-44.29 Million | -0.230x | +8.56% |
| 2009-12-31 | $172.58 Million | $-43.37 Million | -0.251x | -0.84% |
| 2008-12-31 | $168.46 Million | $-41.98 Million | -0.249x | -92.48% |
| 2007-12-31 | $205.67 Million | $-26.63 Million | -0.129x | +14.63% |
| 2006-12-31 | $173.92 Million | $-26.38 Million | -0.152x | -40.32% |
| 2005-12-31 | $190.71 Million | $-20.61 Million | -0.108x | +49.11% |
| 2004-12-31 | $122.06 Million | $-25.93 Million | -0.212x | +7.43% |
| 2003-12-31 | $106.32 Million | $-24.40 Million | -0.229x | +78.23% |
| 2002-12-31 | $29.74 Million | $-31.34 Million | -1.054x | -189.24% |
| 2001-12-31 | $61.54 Million | $-22.42 Million | -0.364x | -71.18% |
| 2000-12-31 | $63.92 Million | $-13.61 Million | -0.213x | +58.99% |
| 1999-12-31 | $26.20 Million | $-13.60 Million | -0.519x | -118.28% |
| 1998-12-31 | $32.80 Million | $-7.80 Million | -0.238x | +36.49% |
| 1997-12-31 | $21.10 Million | $-7.90 Million | -0.374x | +10.75% |
| 1996-12-31 | $23.60 Million | $-9.90 Million | -0.419x | -- |
About Geron Corporation
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company's product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lowe… Read more